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Abstract 
Purpose: Adults presenting with borderline personality disorder (BPD) score poorly on measures of health related 
quality of life (HRQoL). Little is known about HRQoL in adolescents with BPD type presentations and how treatment 
impacts quality of life. Our primary aim was to use routinely collected quality-of-life outcome measures pre and post-
treatment in dialectical behaviour therapy (DBT) for adolescents to address this gap. Secondary aims were to bench-
mark these data against EuroQol 5 dimensions (EQ-5D™) outcomes for clients treated in clinical trials and to assess the 
potential of the EQ-5D™ as a benchmarking tool.
Method: Four adolescent DBT teams, routinely collecting outcome data using a pseudonymised secure web-based 
system, supplied data from consecutive discharges.
Results: Young people in the DBT programmes (n = 43) had severely impaired HRQoL scores that were lower at 
programme admission than those reported in published studies using the EQ-5D™ in adults with a BPD diagnosis 
and in one study of adolescents treated for depression. 40 % of adolescents treated achieved Reliable Clinical Change. 
HRQoL improved between admission and discharge with a large effect size. These results were not statistically signifi-
cant when clustering in programme outcomes was accounted for.
Conclusion: Young people treated in NHS DBT programmes for BPD type presentations had poorer HRQoL than 
adults with a BPD diagnosis and adolescents with depression treated in published clinical trials. The EQ-5D™ detected 
reliable change in this group of adolescents. Programme outcome clustering suggests that both the measure and the 
web-based monitoring system provide a mechanism for benchmarking clinical programmes.
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Background
Whilst borderline personality disorder (BPD) is most 
commonly diagnosed in adults, more recently clinicians 
and researchers have begun to consider the assessment 
and identification of personality disorders in adoles-
cents (Miller et al. 2008; Sharp and Fonagy 2015). Stud-
ies investigating BPD traits in young people report that 
these presentations predict the presence of personal-
ity disorders in adulthood and are also linked to other 
psychiatric disorders, impaired long-term functioning 
and to increased mortality (Cohen et  al. 2005; Craw-
ford et  al. 2008; Winograd et  al. 2008). Currently, there 
are no established effective treatments for young people 
with BPD-type presentations. More typically, adoles-
cent research has focussed on interventions for repeated 
self-harm, one of the diagnostic criteria for BPD. A 
meta-analysis of psychological and social interventions 
for suicide attempts and self-harm (Ougrin et  al. 2015) 
reviewing 19 trials comprising 2176 young people con-
cluded that the selected interventions appeared to be 
effective overall for self-harm. Dialectical behaviour ther-
apy (DBT) (Miller and Rathus 2002; Mehlum et al. 2014), 
cognitive-behavioural therapy (CBT) (Esposito-Smythers 
et  al. 2011) and mentalization-based therapy (MBT) 
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(Roussow and Fonagy 2012) demonstrated the largest 
effect-sizes; however, these results require independent 
replication.
DBT is an effective treatment for BPD in adults with 
robust evidence from randomised controlled trials dem-
onstrating significant impacts on a number of important 
outcomes, including reduced suicidal and self-harming 
behaviours and service utilisation (Clarkin et  al. 2007; 
Koons et al. 2001; Linehan et al. 1991, 1999, 2002, 2006; 
McMain et  al. 2009; Verheul et  al. 2003). The recent 
Cochrane Review concluded that DBT was the only psy-
chological treatment for BPD with sufficient data to pool 
into a meta-analysis (Stoffers et al. 2012). Results demon-
strated moderate to large statistically significant effects 
for DBT over treatment as usual in reductions in suicidal 
and self-harm behaviours (SMD −0.54, 95 % CI −0.92 to 
−0.16); improvements in mental health (SMD 0.65, 95 % 
CI 0.07–1.24) and decreases in anger (SMD −0.83, 95 % 
CI −1.43 to −0.22). The National Institute for Health 
and Care Excellence (NICE) Guidelines for the treatment 
and management of BPD recommend DBT particularly 
where reduction in self-harm is a clinical priority. An ear-
lier review reported that DBT had the potential for cost-
effectiveness (Brazier et al. 2006).
As a direct consequence of its success in treating sui-
cidal and self-harm behaviours with adults diagnosed 
with BPD, DBT was adapted for the treatment of ado-
lescents (DBT-A) presenting with suicidal and self-harm 
behaviours who were also demonstrating features of 
a developing BPD (Miller et  al. 2007). A recent RCT of 
the adapted form of DBT conducted in Norway repli-
cated the findings of earlier studies in adult populations. 
Mehlum et al. (2014) randomly allocated 77 adolescents 
presenting with suicidal and self-harming behaviour with 
at least two other BPD characteristics to either DBT-A or 
Enhanced Treatment as Usual (ETAU). After 16 weeks of 
treatment DBT-A was significantly superior to ETAU in 
terms of decreases in self-harm behaviour and depres-
sion. Several non-randomised studies conducted in the 
UK and elsewhere also indicate that DBT maybe a prom-
ising intervention with adolescents presenting with self-
harm behaviour in the context of BPD (Fleischhaker et al. 
2011; James et al. 2008, 2011; Katz et al. 2004).
Adults diagnosed with BPD have severe impairments in 
Health Related Quality of Life (HRQoL) (van Asselt et al. 
2009; Soeteman et al. 2008; Perseius et al. 2006). In addi-
tion to the significant personal burden of a diagnosis of 
BPD (Heard 2000), clients with BPD are typically “treat-
ment seeking” with associated high utilisation of health 
services (Bender et al. 2001; Benjamin 1993; Coid 2003; 
Lieb et  al. 2004), leading researchers and policy makers 
alike to highlight the importance of investigating and 
implementing clinically and cost-effective treatments for 
this population (Esposito-Smythers et al. 2011; Soeteman 
et  al. 2008). Establishing cost-effectiveness (specifically 
cost-utility analysis) requires generic preference based 
measures that can be used to calculate the cost per addi-
tional Quality-adjusted life year (QALY). QALYs are a 
generic measure of disease burden that includes both the 
quality and length of life and allow for comparison across 
conditions to help inform decision makers where best 
to invest scarce health care resources. NICE (NCCMH 
2009) recommend the EuroQol 5 Dimensions (EQ-5D™) 
as the most appropriate measure for health economic 
evaluations of new technologies. This standardised and 
validated self-report measure describes an individual’s 
current health status and can be used to identify changes 
occurring over time. The construct validity and test–
retest reliability of the EQ-5D™ have also been supported 
(van Asselt et al. 1994).
As the measure is generic rather than condition-spe-
cific, the EQ-5D™ provides a common denominator for 
different evaluations allowing comparison of new tech-
nologies with each other. Such generic measures assess 
broad levels of functioning in contrast to symptomatic 
measures that may address a single clinical outcome e.g. 
self-harm or depression. Whilst individual symptom 
measures are an important measure of clinical outcome, 
clinical guidance recommends considering broader 
measures of functioning and quality of life rather than 
simply symptomatic improvement (NCCMH 2009). Use 
of generic measures maybe of particular importance in 
the case of BPD where clients’ problems impinge on a 
wide range of health domains.
Using the EQ-5D has an additional advantage above 
addressing functional outcomes more broadly; measures 
that enable the calculation of QALYs across a number 
of services will provide data about cost-effectiveness of 
DBT as delivered in routine clinical practice, and, subject 
to sufficient variation across programmes, allow for the 
development of a national benchmarking system. Trans-
ferring evidence-based treatments established as effica-
cious in randomised-controlled clinical trials to routine 
clinical practice is fraught with difficulty (Damschroder 
et al. 2009). Routinely measuring outcomes in clinical set-
tings and benchmarking them against published efficacy 
data provides one method of assessing whether clients 
are benefiting from the treatments they receive. Once 
programmes that do not deliver good clinical outcomes 
can be identified, organisational interventions to address 
poor outcomes can be developed and implemented.
The primary aim of the pilot study was to evaluate 
the HRQoL outcomes of adolescents receiving DBT in 
routine clinical practice. Our secondary aim, given the 
absence of studies reporting on HRQoL in adolescents, 
was to compare the findings with published RCT data 
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on adults with BPD and adolescents with other mental 
health conditions. Finally, we wished to assess the poten-
tial of the EQ-5D™ as a benchmarking measure.
Methods
Procedure
All DBT programmes (N = 9) with a subscription to the 
DBT pseudonymised outcome benchmarking website at 
www.dbt.uk.net were invited to participate in the study. 
The pseudonoymised outcome website was developed to 
assist teams to collect routine outcome data based on the 
potential value of such data for implementation of DBT 
programmes (Swales et  al. 2012). To reduce the admin-
istrative burden on participating programmes and hope-
fully maximise the success of data collection, the amount 
of data required was kept to an absolute minimum using 
a single outcome measure, the EQ-5D™. Consistent with 
keeping the demands on busy programmes low, only 
pre- and post-treatment data were required for entry on 
the website. Programmes were asked to assess clients 
on the EQ-5D™ at admission to the programme and on 
discharge, regardless of whether discharge was planned 
or unplanned. Assessing all entrants to the programme, 
regardless of whether they complete treatment or not, 
provides a more conservative test of the effectiveness of 
a treatment programme. Only including data from treat-
ment completers may overestimate the effectiveness of 
treatment in routine practice. Pseudonyms were selected 
according to the gender of the client so number of male 
and female clients in the sample as a whole is known; 
otherwise no demographic data is available at the indi-
vidual client level.
Seven of the subscribed nine teams were working with 
adolescents. A census of DBT clients in treatment on a 
specified date (1 August 2011) established that only four 
of these programmes were using the website to routinely 
collect data with sufficient accuracy for benchmark-
ing purposes, namely that the website was reporting the 
correct number of clients in treatment that day. Length 
of time programmes had used the website for routine 
data collection varied between 7 (January 2011) and 
16  months (April 2009). These four programmes con-
sented for their data to be downloaded from the system 
on the predefined census date and for their programme 
data to be included in the multi-site data analysis. All 
participating programmes had broadly similar admis-
sion criteria (ages 14–18; five or more BPD criteria of 
which one must be the recent occurrence of self-harm 
behaviour).
All programmes had permission from their infor-
mation governance officers to upload pseudonymised 
routine outcomes to the website. Ethical Approval was 
sought and received from the Ethics Committee of the 
School of Psychology, Bangor University. The Local NHS 
Research Ethics Committee was asked for an opinion on 
whether the study required NHS approval and consid-
ered that the study qualified as service evaluation. No 
patient identified information was submitted to or held 
by the outcome benchmarking website.
Measures
EQ‑5D™
 The EQ-5D™ is a generic outcome measure that asks 
participants to rate their current general health status on 
5 dimensions: mobility, self-care, usual activities, pain or 
discomfort and anxiety and depression. The participant 
rates each of these dimensions at one of three different 
levels (no problems, some problems or extreme prob-
lems). The scoring system then classifies the individual 
into one of 243 possible health states. Each health state 
provides a summary of the participants rating of their 
health status on each dimension. For example, the health 
state ‘11111’ represents perfect health on all 5 dimen-
sions—a state that 56 % of the UK population and 70 % 
of the Spanish population will report on any one day 
(Feng et al. 2015; Gaminde and Roset 2001). In contrast, a 
health status of ‘33333’ indicates the worst possible health 
status with extreme problems on all 5 dimensions. These 
scores can be transformed into a utility score that ranges 
between −0.59 and 1 (with death anchored at 0 and 1 
representing perfect health) by applying societal weights 
to each level that are based on the values of these health 
states in adult general population samples derived from a 
choice based method such as time trade-off (TTO) (Sze-
nde et  al. 2007). Currently there are no weights derived 
from valuations of health states by children and adoles-
cents. Negative scores indicating health states judged as 
‘worse than death’ are possible. The utility scores can be 
used to calculate QALYs. The sole adolescent study utilis-
ing the EQ-5D™ provided tentative support for its use in 
this client group (Byford 2013).
Data collection and entry
Each DBT team had its own protocol for administering 
and entering the data onto the website. In most cases 
young people scored the questionnaires themselves. On 
some occasions clinicians completed the questionnaires 
on their behalf. Proxy completion of the EQ-5D™ is a rec-
ognised method of data collection. In a recent study of 
the EQ-5D™ with children and adolescents from a com-
munity study, where parents acted as proxies, high lev-
els of agreement were found between the self-report and 
proxy versions of the EQ-5D-Y (Gusi et  al. 2014). Each 
DBT team uploaded EQ-5D scores for all patients treated 
in their DBT programme at admission and discharge. An 
audit on a random selection of inputs from each team 
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was conducted to ensure that the data had been accu-
rately entered into the website. To conduct the audit 
one of the research team (LB) telephoned the DBT team 
and asked them to provide the EQ-5D™ scores stored 
on paper in the clinical notes for each client for a set of 
randomly chosen patients and time points. These scores 
were checked for accuracy with the data already entered 
into the website. No inconsistencies between the data 
entered onto the system and the original paper copies of 
the data were detected during this audit.
Data analysis strategy
Utility scores at or below zero might be anticipated in 
clinical samples for which achieving a ‘life worth living’ 
(Linehan 1993) remains a daily struggle. In a sample of 
adolescents in treatment for suicidal and self-harm 
behaviours a measure that captures health states con-
sidered ‘worse than death’ displays considerable face and 
criterion validity; these scores were retained. Difference 
scores were calculated by subtracting EQ-5D™ utility 
scores on discharge from those at admission.
In an endeavour to establish whether the change in 
EQ-5D™ scores represented a robust change at the indi-
vidual level, the Reliable Change Index for the EQ-5D 
was calculated using the Jacobson method (Jacobson and 
Truax 1991). This formula takes into account the reliabil-
ity of the measure and variance in measurement to gen-
erate a change score in excess of which we can essentially 
be 95 % certain that the change in score is a real (hence, 
reliable) change over time. Ideally, in order to exclude 
sources of systematic error in this calculation, an esti-
mate of test-retest reliability derived from a clinical sam-
ple whose clinical characteristics have not changed over a 
period of time would be preferred. Since clinical samples 
are, by definition, in treatment and therefore on a change 
trajectory and the EQ-5D™ is not yet used widely in men-
tal health settings, such estimates are hard to obtain. 
Hurst et al. (1997, Table IX), using an intraclass correla-
tion coefficient (ICC) rather than Pearson correlation 
because of concerns about over-estimating reliability, 
reported a reliability coefficient for the EQ-5D™ of 0.78 
(0.6–0.96) over 2 weeks in a clinical sample of 31 rheu-
matoid arthritis sufferers where there was no change in 
rheumatoid arthritis. More recently Sonntag et al. (2013, 
Table  4) have tabulated ICCs for n  =  106 social pho-
bics at an interval of 6 months and n = 60 at 12 months, 
anchored by no change on the Liebowitz Social Anxiety 
Scale which are all also 0.78. In view of the replication of 
this estimate and albeit limited clinical similarities in the 
study populations, this value was used in the calculation 




On the census date, 76 sets of client data were down-
loaded from four programmes of which 66 had female 
pseudonyms and 10 male. Of these 76 clients, 43 (38 
female and 5 male) had been discharged from their 
respective programme and 33 were still in treatment. 
Admission EQ-5D™ utility scores for the whole sample 
(n = 76) were 0.236 (SD 0.32, range −0.594 to 0.848). The 
admission EQ-5D scores of the 43 adolescents who had 
completed treatment prior to the census date were not 
significantly different from the 33 young people who were 
still in treatment. [Mean admission utility score still in 
treatment (n = 33) = 0.244, mean admission utility score 
discharged (n  =  43)  =  0.230, t(75)  = 0.19, p  =  0.85.] 
Average length of stay of adolescents consecutively dis-
charged from programmes (n  =  43) was 177  days (SD 
116, range 23–462).
Comparison of admission and discharge HRQoL scores
Admission and discharge scores for the 43 consecutive 
discharges in the dataset were compared. Mean admis-
sion utility scores were 0.230 (SD 0.345, range −0.590 to 
0.883) and mean discharge utility scores were 0.554 (SD 
0.376, range −0.008 to 1.000). Fourteen clients reported 
health states as worse than death at admission and nine 
at discharge (Table 1). These data were not normally dis-
tributed and were tested for significance using the Wil-
coxon signed-rank test. Utility scores between admission 
and discharge were significantly different (z  =  −4.26, 
p < 0.001).
Variability between DBT programmes in baseline 
health status on admission (p  <  0.001) and their ability 
to generate changes in EQ-5D scores between admis-
sion and discharge (p  <  0.0001) was apparent in the 
dataset. This was indicative of clustering in the data that 
would exaggerate the significance levels in analyses if not 
accounted for. An intra-programme correlation coeffi-
cient was calculated from the difference scores (treating 
DBT programme as a random effect) and used to inflate 
the width of the estimated confidence interval for mean 
differences to account for between-programme variabil-
ity in outcomes.
The high-level of clustering, indicated by an ICC of 
0.71, increased the variance of the average difference 
score by a factor of approximately 12 according to the 
exact method of calculation for unequal cluster sizes 
given by Donner, Birkett and Buck (Donner et al. 1981). 
The average difference in EQ-5D™ utility scores of 0.32 
between admission and discharge failed to attain statisti-
cal significance once this adjustment was made (t = 1.56, 
p = 0.13).
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The Reliable Change Index calculation indicated that 
EQ-5D™ difference scores of at least 0.45 could be con-
sidered reliable in the present study. Seventeen clients 
in the sample of 43 (40  %) experienced reliable change 
between admission and discharge. The ability of clients 
to achieve change on the EQ-5D™ was constrained by an 
obvious ceiling effect in that over 25 % in the DBT sample 
had a utility score >0.55 on admission and so could not 
achieve a change of >0.45.
Comparison of HRQoL scores with other published data 
sets
Ishak et  al. (2013) identified only 10 studies of psycho-
therapeutic interventions for BPD incorporating the 
use of HRQoL measures, of which only three report the 
EQ-5D™ as an outcome measure (McMain et  al. (2009) 
analyse the Euroqol VAS thermometer but do not report 
the EQ-5D utility scores) and, of these remaining three, 
only two represent unique datasets (van Asselt et  al. 
(2009) re-analyse the Giesen-Bloo et  al. (2006) dataset). 
Both are studies in adult BPD. There is currently limited, 
but promising evidence to support the use of the EQ-5D 
instrument in CAMHS settings as a HRQoL measure 
(Byford 2013).
Baseline and discharge EQ-5D™ scores for this clini-
cal sample of admissions are presented in Table 1, along-
side pre-and post-intervention EQ-5D™ scores from 
the few available RCTs in mental health for comparison 
purposes. As the present study is a small-uncontrolled 
study and primarily of clinical interest in relation to 
benchmarking outcomes across DBT programmes, effect 
sizes using Cohen’s d are also reported. The EQ-5D™ 
scores at treatment commencement are much lower in 
this study than in the studies of BPD in adult popula-
tions (Nadort et  al. (2009), t(103) =  2.15, p  <  0.05; van 
Asselt et al. (2008) t(89) = 2.70, p < 0.005), both of which 
were of Schema-Focussed therapy. The adolescents in 
this pilot study end treatment at an EQ-5D™ score aver-
age commensurate with the starting EQ-5D™ scores of 
adolescents in the RCT for depression (Byford (2013)
t(241) = 0.88, p > 0.02, ns). The effect size for this pilot 
study is higher than the two adult studies (Nadort et al. 
2009; van Asselt et al. 2008) but a similar size to the ado-
lescent depression study (Byford 2013).
Discussion
This study is the first to report on HRQoL of adolescents 
with BPD-type presentations in routine clinical prac-
tice. Participants in the DBT programmes in this study 
had significantly impaired health related quality of life 
(HRQoL) on admission, scoring significantly lower than 
data available from a published RCT using the EQ-5D 
with adult BPD participants (van Asselt et al. 2009) and 
from a study reporting on the treatment of adolescents 
with depression (Byford 2013). These data potentially 
support the often-expressed view of clinicians that cli-
ents in clinical services are more severe than those par-
ticipating in clinical trials. Indeed, this view has been 
highlighted as a barrier to the implementation of evi-
dence-based practice (Shafran et al. 2009).
Alternatively the experience of BPD in adolescence 
compared to adulthood may have a particularly signifi-
cant effect on HRQoL. Typically adolescents presenting 
with developing BPD in adolescence have experienced 
Table 1 Comparison of EQ-5D scores across studies
a Includes 9 clients (21 %) admitted in state 11233 whose utility remained unchanged at −0.008
b Relative to baseline variance which is the effect size commonly used in power calculations, Nadort et al. (2009) calculate effect sizes relative to pooled variance (pre/
post) and report a lower estimate of 0.35
Sample EQ-5D at t1
Mean (95 %  
confidence intervals)
EQ-5D at t2





Average difference Effect size d
Present study: n = 43 routine 
admissions to DBT pro-
grammes
0.23 (0.12–0.34)
EQ-5D < 0 33 %a
0.55 (0.44–0.67)
EQ-5D < 0 21 %a




 Nadort et al. (2009)
n = 62 SFT versus modified SFT 
for adult BPD
0.44 (0.31–0.56) 0.56 (0.47–0.65) 18 months 0.12 (0.02–0.22)
p = 0.02
0.39b
 van Asselt et al. (2008)
n = 48 transference versus SFT 
for adult BPD





n = 199 CBT/SSRI versus SSRI 
for adolescent depression
0.50 (0.46–0.54)
EQ-5D < 0 5.5 %
0.76 (0.72–0.80)
EQ-5D < 0 1.5 %
28 weeks 0.26 (not reported) 0.90
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high levels of adversity in a context of genetic vulnerabil-
ity over many years (Sharp and Fonagy 2015). In addition 
to significant mental health difficulties with high rates 
of comorbidity (Chanen et al. 2007; Ha et al. 2014), they 
encounter major problems at school and with familial 
relationships and friends (Winograd et  al. 2008; Zanar-
ini et  al. 2006; Crawford et  al. 2008) that persist often 
into adulthood even when some of the more impulsive 
behaviours may have subsided. In clinical practice the 
broad ranging impact on almost all aspects of develop-
ment is striking. Poor HRQoL in this context is perhaps 
unsurprising.
Despite the severity of impairment demonstrated in the 
patients treated in the DBT programmes, their HRQoL 
improved between admission and discharge with 40  % 
of the sample achieving Reliable Clinical Change. This 
finding is particularly interesting when considering the 
fact that patients were discharged for multiple reasons—
including both planned (e.g. they completed the DBT 
programme and no longer needed DBT) and unplanned 
discharges (e.g. the patient chose to stop attending treat-
ment). This study reported on the changes between 
admission and discharge for all patients who had received 
DBT regardless of whether they completed the treat-
ment programme or not. This finding also runs counter 
to the views clinicians express (Shafran et al. 2009) that 
increased clinical severity might prevent significant and 
reliable clinical change.
Despite the change in HRQoL scores for patients in 
the DBT programmes, discharge scores remained con-
siderably lower than the general population norm and 
comparable to the scores of adolescents commencing 
treatment in an RCT for depression (Byford 2013). These 
findings underscore the view, reported in the literature, 
that individuals with BPD have significant impairment 
of HRQoL (van Asselt et al. 2009; Soeteman et al. 2008; 
Perseius et  al. 2006) even following what is an effec-
tive treatment. The results suggest that further research 
should be directed towards further enhancing clinical 
outcomes. Typically, adaptations of DBT for adolescents 
have shortened the programme duration from 1  year 
(typical in adult services) to 16  weeks (Mehlum et  al. 
2014; Brazier et al. 2006). The final HRQoL outcomes in 
this study would argue against this given the low level 
of functioning of adolescents at treatment end and that 
adolescents in this study had a longer average treatment 
length than that described in the literature (Mehlum 
et  al. 2014; Miller et  al. 2007). In the shorter forms of 
DBT-A adolescents entering the programme typically 
have fewer BPD symptoms (typically 2–3) whereas in the 
clinical programmes studied here inclusion criteria to the 
programme required 5 or more BPD criteria which may 
account for the longer treatment duration. These results 
suggest that for adolescents at this level of severity longer 
treatment durations may be necessary.
Not all of the programmes were equally successful 
in producing good HRQoL outcomes. When this vari-
ability was accounted for outcomes were not significantly 
different at treatment end. The level of clustering in the 
dataset (ICC of 0.71) is unusually high, beyond the range 
commonly encountered in naturally occurring biologi-
cal and disease-related phenomena. Such variability is 
perhaps not uncommon in pilot data, especially with a 
team-based treatment delivered within highly variable 
organisational contexts. Whether the high levels of clus-
tering were driven by differences in programme fidel-
ity or therapist competence or are simply the artefact 
of small numbers of participants with a condition with 
highly variable outcomes is unknown. Future studies with 
more programmes with larger numbers of teams and 
treated clients will be necessary to tease out this find-
ing. Paradoxically, the differential success of the DBT 
programmes in producing HRQoL outcomes, with some 
programmes performing better than others, augurs well 
for the intended use of the website for future benchmark-
ing between programmes.
Whilst these findings in this pilot study are of interest, 
aspects of the data collection indicate that they should be 
interpreted with a significant degree of caution. Firstly, 
only four out of seven CAMHS teams with a subscription 
to the website were successfully using the system to col-
lect routine data. The teams that were collecting data may 
have been especially motivated and thus potentially have 
been more likely to produce improved outcomes. Resolv-
ing problems in routinely collecting outcomes using the 
system would be essential for future meaningful use of 
the system to collect national outcome data or to bench-
mark programmes systematically. Secondly, these data 
were collected under routine clinical practice conditions 
and so the research team did not control data collection 
and entry. Each individual DBT programme operated 
their own data administration, collection and entry pro-
cedures for their own clinical purposes and this may have 
led to different protocols for data collection. In some 
teams the proportion of EQ-5Ds completed by clinicians 
as a proxy, may have been higher and in some cases cli-
nicians recorded the measure retrospectively, particu-
larly in circumstances where patients left the programme 
prematurely. Both of these practices may have resulted in 
biases in the data. Secondly, the absence of any additional 
data on either the participants or other outcomes limits 
generalizability. Thirdly, the absence of a control group 
means that change in the sample cannot be attributed to 
the treatment that they received. The absence of a control 
group and the high-level of clustering means that these 
data cannot make any definitive statement about whether 
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DBT is effective in adolescents with BPD treated in rou-
tine clinical practice.
In conclusion, although further research is necessary to 
unpick the findings of this pilot study, the DBT outcome 
monitoring website has demonstrated its potential to col-
lect data in routine practice and in real-time and thus 
may be a promising tool to benchmark what is gained 
and lost following the implementation of DBT in clinical 
practice settings.
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